Home    Back

1.0 miu il-2 per day    (DrugBank: IL-2)

1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02059759
(ClinicalTrials.gov)		September 20157/2/2014Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2Amyotrophic Lateral SclerosisDrug: Placebo;Drug: 1.0 MIU IL-2 per day;Drug: 2.0 MIU IL-2 per dayCentre Hospitalier Universitaire de NimesNULLCompleted18 Years75 YearsBoth36Phase 2France